Biohaven (BHVN) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Biohaven (NYSE: BHVN):

• 12/1/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Biohaven was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a $11.00 price target on the stock, down previously from $26.00.
• 11/24/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Biohaven had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Biohaven had its price target lowered by analysts at Morgan Stanley from $54.00 to $26.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Biohaven had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $16.00 price target on the stock.
• 11/17/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Biohaven had its price target lowered by analysts at Citigroup Inc. from $28.00 to $14.00. They now have a “buy” rating on the stock.
• 11/11/2025 – Biohaven had its “market perform” rating reaffirmed by analysts at William Blair.
• 11/6/2025 – Biohaven had its price target lowered by analysts at Royal Bank Of Canada from $19.00 to $9.00. They now have a “sector perform” rating on the stock.
• 11/6/2025 – Biohaven had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $9.00 price target on the stock, down previously from $34.00.
• 11/6/2025 – Biohaven had its price target lowered by analysts at BTIG Research from $33.00 to $16.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Biohaven had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 11/5/2025 – Biohaven had its “hold” rating reaffirmed by analysts at William Blair.
• 11/5/2025 – Biohaven had its “overweight” rating reaffirmed by analysts at Morgan Stanley.
• 11/5/2025 – Biohaven had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..
• 11/5/2025 – Biohaven was given a new $42.00 price target on by analysts at Robert W. Baird.
• 11/5/2025 – Biohaven was downgraded by analysts at Bank of America Corporation from a “buy” rating to a “neutral” rating. They now have a $10.00 price target on the stock.
• 11/5/2025 – Biohaven had its price target lowered by analysts at TD Cowen from $50.00 to $15.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Biohaven had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In other news, Director John W. Childs purchased 3,333,333 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average cost of $7.50 per share, with a total value of $24,999,997.50. Following the acquisition, the director directly owned 5,653,904 shares of the company’s stock, valued at approximately $42,404,280. This trade represents a 143.64% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gregory Bailey acquired 400,000 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the director directly owned 2,020,071 shares of the company’s stock, valued at approximately $15,150,532.50. The trade was a 24.69% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 4,416,999 shares of company stock valued at $33,144,833. Company insiders own 14.60% of the company’s stock.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.